# Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

> **NCT02268747** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 43 (estimated)

## Conditions studied

- Skin Squamous Cell Cancer

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT02268747
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2016-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268747, "Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02268747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*